LLY · News · 20261030N

Competition and market share - weight-loss

ELI LILLY & Co · 2026-10-30 · Importance 17 · Surprise 24

Third-party reporting said Lilly trial data showed retatrutide outperforming Novo Nordisk’s Ozempic. The report characterized the data as sharpening the competitive focus on Novo Nordisk as the company sets longer-term goals. No trial measurements or market-share figures were provided in the digest.

Key facts